Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeuroOne Medical TechnologiesNMTC -7.41%21 3-1 Month Momentum % is -50.90% as of Aug. 27, 2026. GuruFocus rates NMTC with a GF Score™ of 21/100. The stock has 4 warning signs investors should review. Among 852 Medical Devices & Instruments companies, NeuroOne Medical Technologies ranks worse than 95.66% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-27), NeuroOne Medical Technologies's 3-1 Month Momentum % is -50.90%.
The industry rank for NeuroOne Medical Technologies's 3-1 Month Momentum % or its related term are showing as below:
NMTC's 3-1 Month Momentum % is ranked worse than 95.66% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: -7.71
vs NMTC: -50.90
NeuroOne Medical Technologies (NAS:NMTC) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
NeuroOne Medical Technologies 3-1 Month Momentum % Related Terms
NMTC vs CSDX, IRIX, LFWD: 3-1 Month Momentum % Comparison
For the Medical Devices subindustry, NeuroOne Medical Technologies's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuroOne Medical Technologies 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NeuroOne Medical Technologies's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where NeuroOne Medical Technologies's 3-1 Month Momentum % falls into.
NeuroOne Medical Technologies (NAS:NMTC) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuroOne Medical Technologies (NMTC) has a 3-1 Month Momentum % of -50.90% as of Aug. 27, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on NeuroOne Medical Technologies and its competitors. According to the industry distribution chart, NeuroOne Medical Technologies ranks #815 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 95.7%.
Is NeuroOne Medical Technologies' 3-1 Month Momentum % too high?
NeuroOne Medical Technologies' current 3-1 Month Momentum % is -50.90%. Based on the distribution chart, NeuroOne Medical Technologies ranks #815 out of 852 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, NeuroOne Medical Technologies has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does NeuroOne Medical Technologies' 3-1 Month Momentum % compare to CSDX and IRIX?
According to the Medical Devices & Instruments industry distribution chart, NeuroOne Medical Technologies ranks #815 out of 852 companies for 3-1 Month Momentum %. This places NeuroOne Medical Technologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on NeuroOne Medical Technologies and its competitors. NeuroOne Medical Technologies's current 3-1 Month Momentum % is -50.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroOne Medical Technologies stock overvalued right now?
NeuroOne Medical Technologies (NMTC) has a current 3-1 Month Momentum % of -50.90%. The current 3-1 Month Momentum % is -50.90%. NeuroOne Medical Technologies' overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For NeuroOne Medical Technologies (NMTC), the current 3-1 Month Momentum % is -50.90% as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
21GF Score
Get the complete analysis for NMTC
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NMTC has been successfully added to your 
